Ivy Cosmetics Corporation
Notification Regarding Grant of Patent Following National Phase Entry of International (PCT) Application for Anti-Cancer Substance (New Compound) on November 19, 2026
A patent grant was received at the national phase for the new anti-cancer substance "24-position di-substituted cholesterol glycoside." The co-applicant is Kogakuin University. The Company will consider licensing agreements and applications in the pharmaceutical field, suggesting potential license fee revenues within the patent term. There are many uncertainties, and the impact on financial results is TBD.
Key Figures
- Patent term: Until September 17, 2045
- Future potential for license fees: uncertain, not specified
- Joint application: 50:50 rights ratio with Kogakuin University
AI要約
Overview and Business Significance
The receipt today of a patent grant following the PCT national phase entry for the anti-cancer substance "24-position di-substituted cholesterol glycoside" means that the joint development results between Kogakuin University and Ivy Cosmetics Corporation will be legally protected. Following registration of the patent right, the Company plans to promote practical social use through licensing to pharmaceutical manufacturers. The patent is a composition-of-matter patent, enabling the right holder to exclusively manufacture and sell the compound. There is a possibility of long-term license revenue.
Impact and Future Actions
The invention has high potential for industrial application, and licensing agreements assuming applications in the pharmaceutical field are expected. The patent term is valid until September 17, 2045, with a possible extension mechanism of up to 5 years for pharmaceuticals. The direct immediate impact on financial results is TBD, and the Company intends to seek milestone-based contracts. Progress in related development and the status of license agreements will be disclosed going forward.
Ivy Cosmetics Corporation
Company overview · Stock price · Financial data · All IR